|
1
|
Abrahamsson PA, Wadström LB, Alumets J, et
al: Peptide-hormone- and serotonin-immunoreactive tumour cells in
carcinoma of the prostate. Pathol Res Pract. 182:298–307. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Komiya A, Suzuki H, Imamoto T, et al:
Neuroendocrine differentiation in the progression of prostate
cancer. Int J Urol. 16:37–44. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cussenot O, Villette JM, Cochand-Priollet
B and Berthon P: Evaluation and clinical value of neuroendocrine
differentiation in human prostatic tumors. Prostate Suppl. 8:43–51.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weaver MG, Abdul-Karim FW and Srigley JR:
Paneth cell-like change and small cell carcinoma of the prostate.
Two divergent forms of prostatic neuroendocrine differentiation. Am
J Surg Pathol. 16:1013–1016. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Helpap B and Köllermann J:
Undifferentiated carcinoma of the prostate with small cell
features: immunohistochemical subtyping and reflections on
histogenesis. Virchows Arch. 434:385–391. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
di Sant’Agnese PA: Neuroendocrine
differentiation in carcinoma of the prostate. Diagnostic,
prognostic, and therapeutic implications. Cancer. 70(1 Suppl):
254–268. 1992.
|
|
7
|
Amato RJ, Logothetis CJ, Hallinan R, Ro
JY, Sella A and Dexeus FH: Chemotherapy for small cell carcinoma of
prostatic origin. J Urol. 147:935–937. 1992.PubMed/NCBI
|
|
8
|
Sella A, Konichezky M, Flex D, Sulkes A
and Baniel J: Low PSA metastatic androgen- independent prostate
cancer. Eur Urol. 38:250–254. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oesterling JE, Hauzeur CG and Farrow GM:
Small cell anaplastic carcinoma of the prostate: A clinical,
pathological and immunohistological study of 27 patients. J Urol.
147:804–807. 1992.PubMed/NCBI
|
|
10
|
Miyoshi Y, Uemura H, Kitami K, Satomi Y,
Kubota Y and Hosaka M: Neuroendocrine differentiated small cell
carcinoma presenting as recurrent prostate cancer after androgen
deprivation therapy. BJU Int. 88:982–983. 2001. View Article : Google Scholar
|
|
11
|
Tanaka M, Suzuki Y, Takaoka K, et al:
Progression of prostate cancer to neuroendocrine cell tumor. Int J
Urol. 8:431–436. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hvamstad T, Jordal A, Hekmat N, Paus E and
Fosså SD: Neuroendocrine serum tumour markers in hormone-resistant
prostate cancer. Eur Urol. 44:215–221. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deng X, Liu H, Huang J, et al: Ionizing
radiation induces prostate cancer neuroendocrine differentiation
through interplay of CREB and ATF2: implications for disease
progression. Cancer Res. 68:9663–9670. 2008. View Article : Google Scholar
|
|
14
|
Deng X, Elzey BD, Poulson JM, et al:
Ionizing radiation induces neuroendocrine differentiation of
prostate cancer cells in vitro, in vivo and in prostate cancer
patients. Am J Cancer Res. 1:834–844. 2011.PubMed/NCBI
|
|
15
|
D’Amico AV, Whittington R, Malkowicz SB,
et al: Biochemical outcome after radical prostatectomy, external
beam radiation therapy, or interstitial radiation therapy for
clinically localized prostate cancer. JAMA. 280:969–974. 1998.
|
|
16
|
Asmis TR, Reaume MN, Dahrouge S and Malone
S: Genitourinary small cell carcinoma: a retrospective review of
treatment and survival patterns at The Ottawa Hospital Regional
Cancer Center. BJU Int. 97:711–715. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yao JL, Huang J and di Sant’Agnese PA:
Small cell carcinoma of the prostate. Diagn Histopathol.
14:117–121. 2008. View Article : Google Scholar
|
|
18
|
Sasaki T, Komiya A, Suzuki H, et al:
Changes in chromogranin a serum levels during endocrine therapy in
metastatic prostate cancer patients. Eur Urol. 48:224–229. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hansel DE, Nakayama M, Luo J, et al:
Shared TP53 gene mutation in morphologically and phenotypically
distinct concurrent primary small cell neuroendocrine carcinoma and
adenocarcinoma of the prostate. Prostate. 69:603–609. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Williamson SR, Zhang S, Yao JL, et al:
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic
adenocarcinoma and prostatic small cell carcinoma and absent in
small cell carcinoma of the urinary bladder: evidence supporting
monoclonal origin. Mod Pathol. 24:1120–1127. 2011. View Article : Google Scholar
|
|
21
|
Têtu B, Ro JY, Ayala AG, Johnson DE,
Logothetis CJ and Ordonez NG: Small cell carcinoma of the prostate.
Part I A clinicopathologic study of 20 cases. Cancer. 59:1803–1809.
1987.PubMed/NCBI
|
|
22
|
Noda K, Nishiwaki Y, Kawahara M, et al
Japan Clinical Oncology Group: Irinotecan plus cisplatin compared
with etoposide plus cisplatin for extensive small-cell lung cancer.
N Engl J Med. 346:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Deorah S, Rao MB, Raman R, Gaitonde K and
Donovan JF: Survival of patients with small cell carcinoma of the
prostate during 1973–2003: a population-based study. BJU Int.
109:824–830. 2012.
|
